• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Spermosens

0.01 SEK

-6.00 %

Less than 1K followers

SPERM

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-6.00 %
-9.62 %
+2.17 %
+62.07 %
+46.88 %
+34.29 %
-94.48 %
-99.33 %
-99.03 %

Spermosens operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical support and potential fertilization. The largest operations are found in the Nordic market.

Read more
Market cap
29.83M SEK
Turnover
52.55K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18/6
2026

General meeting '26

20/8
2026

Interim report Q2'26

12/11
2026

Interim report Q3'26

Regulatory press release5/28/2026, 1:45 PM

Spermosens publishes annual report for the financial year 2025

Spermosens
Regulatory press release5/28/2026, 1:39 PM

Spermosens publicerar årsredovisning för räkenskapsåret 2025

Spermosens
Regulatory press release5/18/2026, 7:14 AM

Spermosens: NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)

Spermosens

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/18/2026, 7:11 AM

Spermosens: KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)

Spermosens
Press release5/11/2026, 1:59 PM

Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026

Spermosens
Regulatory press release5/7/2026, 4:08 PM

Spermosens secures SEK 4.85 million capital facility to support development and commercialization

Spermosens
Regulatory press release5/7/2026, 6:37 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - MARCH 2026

Spermosens
Press release4/29/2026, 12:30 PM

Spermosens reports JUNO-Checked Generation 3 clinical validation study on track

Spermosens
Regulatory press release4/8/2026, 12:32 PM

Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study

Spermosens
Press release3/25/2026, 10:55 AM

Spermosens AB (publ) Issues Final Reminder for Tomorrow's Live Q&A Webcast

Spermosens
Press release3/16/2026, 3:13 PM

Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress

Spermosens
Regulatory press release2/11/2026, 8:58 AM

Spermosens AB (publ)YEAR-END REPORT JANUARY - DECEMBER 2025 - CORRECTED

Spermosens
Regulatory press release2/11/2026, 8:05 AM

Spermosens AB (publ)YEAR-END REPORT JANUARY - DECEMBER 2025

Spermosens
Regulatory press release1/26/2026, 12:40 PM

Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

Spermosens
Regulatory press release1/16/2026, 9:22 AM

Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics

Spermosens
Regulatory press release12/9/2025, 7:45 AM

Spermosens shares progress and plans for partner-driven commercialization

Spermosens
Regulatory press release12/8/2025, 12:41 PM

Spermosens announces outcome of exercise of warrants series TO 4

Spermosens
Regulatory press release11/24/2025, 4:12 PM

Spermosens announces last day of trading for warrants of series TO 4

Spermosens
Regulatory press release11/18/2025, 9:21 AM

Spermosens receives patent approval in China

Spermosens
Regulatory press release11/12/2025, 8:04 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

Spermosens